Scientific Research

Valnivudine™ (formerly FV-100) Featured Research

41st Annual International Herpesvirus Workshop, Madiscon, WI; July 23 – 27 2016 Robert Noveck et al.

Antiviral Chemistry & Chemotherapy (2009) 20
Marco Migliore

Journal of Antimicrobial Chemotherapy (2009) 64, 671–673, Advance Access publication August 13, 2009
McGuigan C, Balzarini J.

22nd Annual International Conference on Antiviral Research (ICAR), Miami Beach, FL; May 3 – 7, 2009
Dr. Mark Matson et al.

22nd Annual International Conference on Antiviral Research (ICAR), Miami Beach, FL; May 3 – 7, 2009
Dr. Mark Matson et al.

Valnivudine™ (formerly FV-100) Supporting Research

Antiviral Research, 2006 Sep;71(2-3): 149-153.
McGuigan C, Balzarini J.

Andrei G, Sienaert, McGuigan C2 De Clercq E, Balzarini J, Snoeck R.
Antimicrobial Agents and Chemotherapy, 2005 Mar.; 49 (3): 1081-1086.

Journal of Antimicrobial Chemotherapy, 2002 Jul;50(1): 5-9.
Balzarini J, McGuigan C.

Molecular Pharmacology, 2002 May;61(5): 1140-1145.
Balzarini J, Sienaert R, Liekens S, Van Kuilenburg A, Carangio A, Esnouf R, De Clercq E, McGuigan C.

Pharmaceutical Research, 2004 June;21(6): 914-919.
Jarvis C, McGuigan C, Heard C.

Molecular Pharmacology, 2000 Nov;58(5): 1109-1114.
Li L, Dutschman G, Gullen E, Tsujii E, Grill S, Choi Y, Chu C, Cheng Y.

List View

1. FV-100: the most potent and selective anti-varicella zoster virus agent reported to date
Antiviral Chemistry & Chemotherapy (2009) 20
Marco Migliore

2. FV100 as a new approach for the possible treatment of varicella-zoster virus infection
Journal of Antimicrobial Chemotherapy (2009) 64, 671–673, Advance Access publication August 13, 2009
McGuigan C, Balzarini J.

3. A Study of the Safety and Pharmacokinetics of Single and Multiple Doses of FV-100 in Subjects 65 Years and Over
22nd Annual International Conference on Antiviral Research (ICAR), Miami Beach, FL; May 3 – 7, 2009
Dr. Mark Matson et al.

4. A Study of the Safety and Pharmacokinetics of Multiple Ascending Doses of FV-100 in Healthy Subjects
22nd Annual International Conference on Antiviral Research (ICAR), Miami Beach, FL; May 3 – 7, 2009
Dr. Mark Matson et al.

5. Aryl Furano Pyrimidines: The Most Potent and Selective Anti-VZV Agents Reported to Date
Antiviral Research, 2006 Sep;71(2-3): 149-153.
McGuigan C, Balzarini J.

6. Susceptibilities of Several Clinical Varicella-Zoster Virus (VZV) Isolates and Drug-Resistant VZV Strains to Bicyclic Furano Pyrimidine Nucleosides
Andrei G, Sienaert, McGuigan C2 De Clercq E, Balzarini J, Snoeck R.
Antimicrobial Agents and Chemotherapy, 2005 Mar.; 49 (3): 1081-1086.

7. Bicyclic Pyrimidine Nucleoside Analogues (BCNAs) as Highly Selective and Potent Inhibitors of Varicella-Zoster Virus Replication
Journal of Antimicrobial Chemotherapy, 2002 Jul;50(1): 5-9.
Balzarini J, McGuigan C.

8. Lack of Susceptibility of Bicyclic Nucleoside Analogs, Highly Potent Inhibitors of Varicella-Zoster Virus, to the Catabolic Action of Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase
Molecular Pharmacology, 2002 May;61(5): 1140-1145.
Balzarini J, Sienaert R, Liekens S, Van Kuilenburg A, Carangio A, Esnouf R, De Clercq E, McGuigan C.

9. Specific Recognition of the Bicyclic Pyrimidine Nucleoside Analogs, a New Class of Highly Potent and Selective Inhibitors of Varicella-Zoster Virus (VZV), by the VZV-Encoded Thymidine Kinase
Molecular Pharmacology, 2002 Feb;61(2):249-254.
Sienaert R, Naesens L, Brancale A, De Clercq E, McGuigan C, Balzarini J.

10. In Vitro Delivery of Novel, Highly Potent Anti-Varicella Zoster Virus Nucleoside Analogues to their Target Site in the Skin
Pharmaceutical Research, 2004 June;21(6): 914-919.
Jarvis C, McGuigan C, Heard C.

11. Metabolism and Mode of Inhibition of Varicella-Zoster Virus by L-β-5-Bromovinyl-(2-hydroxymethyl)-(1,3-dioxolanyl)uracil Is Dependent on Viral Thymidine Kinase
Molecular Pharmacology, 2000 Nov;58(5): 1109-1114.
Li L, Dutschman G, Gullen E, Tsujii E, Grill S, Choi Y, Chu C, Cheng Y.